Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — BIO 2023
19 slides from Enveric Biosciences's conference presentation, Jun 6, 2023
Slide 1: Enveric Biosciences - Next Generation Mental Health
ENVSR IG BIOSCIENCES Non-Confidential Deck BIO 2023 ww Next Generation Mental Health™
Slide 2: High Unmet Need of Anxiety and Other Mental Health Disorders
High Unmet Need of Anxiety and Other Mental Health Disorders + Anxiety disorders are among the most common CNS Disorders, ranking second. + Anxiety disorders are chronic conditions that remain poorly controlled despite available treatments. + The last FDA-approved drug to treat Generalized Anxiety D
Slide 3: Limitations of Current Anxiety Pharmacologic Treatments
Limitations of Current Anxiety Pharmacologic Treatments Anxiolytics: 1st Generation Psilocybin: + Benzodiazepines (BZD) + Currently under investigation + Selective serotonin reuptake inhibitors (SSRIs) + Challenges with patentability + Serotonin norepinephrine reuptake inhibitors (SNRIs) * Anecdotal
Slide 4: New Paradigm in Mental Health
New Paradigm in Mental Health 1. Clinical data shows serotonin analogs that bind 5HT2AR (e.g. psilocin) + psychotherapy result in high response rate in MDD, TRD, other 2. Academic work dependent upon available psychedelics * Hallucinations, neuroplasticity both present * Commercial shortcomings: + S
Slide 5: Solving the Commercial Shortcomings of Psilocybin
Solving the Commercial Shortcomings of Psilocybin 1. Different psilocin prodrug or deuterated psilocybin / psilocin 1. NCE for IP, yet can still leverage existing psilocybin data from others 2. MARKET PREMISE: 1. Novel treatment for mental illness targeting different mechanism of action compared to
Slide 6: EVM201 and EVM301 Programs
EVM201 and EVM301 Programs EVM201 EVM301 (novel psilocin prodrug) (novel CNS drug) “Ry i N— x NH2 Inspired by Inspired by HO Psilocybin Psilocin
Slide 7: EVM301 Program
EVM301 Program Non-hallucinogenic Improved Safety Profile f? v Novel molecules that bind 5HT2AR, induce intelli g a neuroplasticity, but without inducing hallucinations tryptamines
Slide 8: EVM301: Peer review and patents
EVM301: Peer review and patents Peer Review + Preprints + Chen et al (2023) Bioproduction platform using a novel cane toad (Rhinella marina) N-methyltransferase for psychedelic-inspired drug discovery + Posters + Matinkhoo et al. Canadian Chemistry Conference and Exhibition. (2023) Design, synthesis
Slide 9: EVM301 Program Critical Path
EVM301 Program Critical Path IP assessment In silico assessment Approval Design + Patentability + Molecular docking * clo Build Unit —> + FTO — > + Molecular dynamics ©=——> — unit + Safety and toxicity Hallucination models Neuroplasticity models Efficacy models Drug Hit + PsychLight + Cell-based ELI
Slide 10: Intelligent Design of Non-Hallucinogenic Neuroplastinogens
Intelligent Design of Non-Hallucinogenic Neuroplastinogens Proprietary molecular dynamic simulation is used to design novel non-hallucinogenic SHT2A-binding molecules * Molecules are initially tested using the PsychLight cellular biosensor tool prior to mouse HTR assays + The resulting high ‘hit’ ra
Slide 11: Non-hallucinogenic hits show neuroplasticity similar or superior to DMT
+ Non-hallucinogenic hits generally show neuroplasticity similar or superior to DMT + Hits also show efficacy in mouse behavioral models, including sucrose-preference and marble-burying assays Tryptophan MM791
Slide 12: Hit-to-Lead
Hit-to-Lead + Process operating + First step is elimination of designs not protected by existing Enveric Composition-of-Matter IP * Proprietary neuroplasticity, hallucination prediction and rapid in vivo assays created and essential elements of process Leads + Numerous leads in hand already * Buildi
Slide 13: EVM201 Program: Building a better psilocybin
EVM201 Progra Building a better psilocybin FLEXIBLE DELIVERY ROUTE y Can be administered via oral, intra-nasal, buccal or Rationally desi i intravenous route the active met | pharmacoki achieve impr profile 13
Slide 14: EVM201: Peer review and patents
EVM201: Peer review and patents Peer Review + Preprints + Raithatha et al. (2023) Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders + Posters + Raithatha et al. (2023) Canadian Chemistry Conference and Exhibition. Novel p
Slide 15: EVM201 Program
EVM201 Program + Release of psilocin from £B373 more rapid than from psilocybin * Release in liver and blood, in addition to intestine, expands administration modes compared with psilocybin * More rapid decline in plasma psilocin levels potentially reduces period of hallucination + £B373 as effectiv
Slide 16: Phase 1 Study
Phase 1 Study Three escalating cohorts Normal healthy volunteers TOXICOLOGY In-vitro Tox | non-GLP DRF rodent + large species GLP Repeat dose Tox rodent + large species GLP Safety Pharm | Gene |Repro| Resp/Card/CNS CMC DS Process Development | GMP DP Process Development | GMP. Placebo controlled
Slide 17: Phase 2 Study
Phase 1 Study NHV|SAD|PBO controlled Phase 2a in GAD (Australia) No response to SSRI/SNRI/BZD Phase 2b in GAD (Global) DBPC | Three arm | Parallel groups N= 180 patients with GAD No response to SSRI/SNRI/BZD iy)
Slide 18: Partner Opportunities
Partner Opportunities Seeking Co-Development Partners EB-373 EVM201 EVM301 Select EVM301 candidate(s) Other structural cores e.g. mescaline, MDMA e@aoga 18
Slide 19: Enveric - Contact
ENVERIGh aa Mental Health™ O252e EN) © ESS) Joseph Tucker, PhD CEO jtucker@enveric.com 508-627-0485